Characteristic | Patients with SOF/VEL±RBV | Patients with GLE/PIB | P-value |
Population, % (n) | 60.5% (46) | 39.5% (30) | |
Males, % (n) | 78.3% (36) | 66.7% (20) | 0.39 |
Age, mean (years±SD) | 48,72±9,41 | 47,03±11,32 | 0.5 |
Age≥65 years, % (n) | 4.3% (2) | 6.6% (2) | 0.93 |
HIV co-infection, % (n) | 13.0% (6) | 0.0% (0) | 0.1 |
Fibrosis stage, % (n) | |||
F0-1 | 54.3% (25) | 53.3% (16) | 0.88 |
F2 | 19.6% (9) | 16.7% (5) | 0.99 |
F3 | 6.5% (3) | 20.0% (6) | 0.16 |
F4 | 19.6% (9) | 10.0% (3) | 0.43 |
Previous clinical decompensation, % (n) | 2.2% (1) | 0.0% (0) | 0.83 |
CTP classification, % (n) | |||
A | 19.6% (9) | 10.0% (3) | 0.43 |
B | 0.0% (0) | 0.0% (0) | >0.99 |
C | 0.0% (0) | 0.0% (0) | >0.99 |
Hepatocellular carcinoma, % (n) | 4.3% (2) | 0.0% (0) | 0.67 |
Liver transplant, % (n) | 2.2% (1) | 0.0% (0) | 0.83 |
HCV viral load, log UI/mL (mean±SD) | 6,13±0.80 | 5,97±0.95 | 0.45 |
Estimated glomerular filtration rate<60 mL/min, % (n) | 2.2% (1) | 0.0% (0) | 0.83 |
Previous antiviral treatment, % (n) | |||
Naïve | 93,5% (43) | 90,0% (27) | 0.91 |
Treatment-experienced | 6,5% (3) | 10% (3) | |
Response to previous antiviral treatment, % (n) | |||
Recidivant | 0.0% (0) | 6.7% (2) | 0.3 |
Reinfection | 2.2% (1) | 0.0% (0) | 0.83 |
Null responder | 2.2% (1) | 0.0% (0) | 0.83 |
Unknown | 2.2% (1) | 3.3% (1) | 0.67 |
CPT, Child-Pugh-Turcotte; GLE/PIB, glecaprevir/pibrentasvir; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SOF/VEL±RBV, sofosbuvir/velpatasvir±ribavirin.